Seeking Alpha

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in ...
Seeking Alpha

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results

- Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the ...
Nasdaq

Pyxis Oncology Initiates Phase 1/2 Trial for PYX-201 in Combination with KEYTRUDA® for Advanced Solid Tumors

Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical trials ...
FierceBiotech

Pyxis puts 2 drugs on backburner and a 3rd on the scrapheap to rally resources behind lead cancer programs

Pyxis Oncology is slimming down after a tough start to life on public markets, pausing work on two assets and stopping development of a third altogether to focus its cash on getting its lead programs ...
FierceBiotech

To pave a longer runway, Pyxis to cut staff, reprioritize and offload brand-new Apexigen assets

Pyxis Oncology needs to pave a longer cash runway. To do so, the Pfizer-partnered antibody-drug conjugate (ADC) biotech is cutting 40% of staff, slimming its programs and looking to monetize royalty ...